Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage

Sangkyu Park1,2, Jeong-A Park1,2, Jae-Hyung Jeon1 and Younghee Lee1,2,*

1Department of Biochemistry, College of Natural Sciences, Chungbuk National University, Cheongju 28644, 2Biotechnology Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea

Abstract

HSP90 is a molecular chaperone that increases the stability of client proteins. Cancer cells show higher HSP90 expression than normal cells because many client proteins play an important role in the growth and survival of cancer cells. HSP90 inhibitors mainly bind to the ATP binding site of HSP90 and inhibit HSP90 activity, and these inhibitors can be distinguished as ansamycin and non-ansamycin depending on the structure. In addition, the histone deacetylase inhibitors inhibit the activity of HSP90 through acetylation of HSP90. These HSP90 inhibitors have undergone or are undergoing clinical trials for the treatment of cancer. On the other hand, recent studies have reported that various reagents induce cleavage of HSP90, resulting in reduced HSP90 client proteins and growth suppression in cancer cells. Cleavage of HSP90 can be divided into enzymatic cleavage and non-enzymatic cleavage. Therefore, reagents inducing cleavage of HSP90 can be classified as another class of HSP90 inhibitors. We discuss that the cleavage of HSP90 can be another mechanism in the cancer treatment by HSP90 inhibition.

Key Words: HSP90 inhibitors, Anti-cancer therapy, ATP binding, Acetylation, HSP90 cleavage

INTRODUCTION

Most living organisms commonly express heat shock proteins and their expression increases in response to a variety of stresses (Welch, 1993). Heat shock-induced expression of genes was first discovered in chromosomal puffing by heat shock in Drosophila busckii in 1962 (Ritossa, 1962). In 1974, it was first reported that the synthesis of a few proteins was enhanced by stresses such as heat shock in Drosophila cells (Tissieres et al., 1974). Heat shock protein 90 (HSP90) is a member of the heat shock protein family and functions as a molecular chaperone that supports the stability of client proteins. Typical examples of the client proteins are mutated p53, Bcr-Abl, Raf-1, Akt, human epidermal growth factor 2 (Her2/ErbB2), HIF-1α, etc. (Neckers and Workman, 2012).

HSP90 is evolutionarily conserved and has many isoforms, such as HSP90α, HSP90β, Grp94, and HSP75/TRAP1. Among these isoforms, HSP90α and HSP90β are localized in cytosol, HSP90α (major form) is constitutively expressed, and expression of HSP90β (minor form) is inducible (Sreedhar et al., 2004). HSP90 consists of three domains, N-terminal domain (N-domain), middle domain (M-domain), and C-terminal domain (C-domain). The N-domain has an ATP-binding pocket and ATPase activity (Prodromou et al., 1997). HSP90 forms a flexible dimer by interaction of C-domains. The formation and dissociation of compact dimers involving N-domains is important for the molecular chaperone activity (Rohl et al., 2013). Binding of ATP to the ATP-binding pocket of the N-domain promotes dimerization between the two N-domains, and the ATPase activity of the N-domain induces the hydrolysis of ATP to ADP, resulting in N-domain dissociation (Prodromou et al., 2000; Richter and Buchner, 2001). HSP90 requires co-chaperones, such as cdc37, Hop, p23, PP5, and Xap2, to function as a molecular chaperone. Co-chaperones interact with HSP90 and regulate ATPase activity for molecular chaperone activity of HSP90 and recruit client proteins to HSP90 (Zuehlke and Johnson, 2010; Rohl et al., 2013).

In most cancer cells, HSP90 and its client proteins are expressed at higher levels than normal cells. The client proteins, such as Her2/ErbB2, v-Src, Raf-1, Akt, hTERT, are important for cancer cell survival and growth (Ferrarini et al., 1992; Sharp and Workman, 2006; Miyata et al., 2013) (Table 1). HSP90 is...
HSP90 INHIBITORS BLOCKING ATP BINDING

HSP90 inhibitors generally interrupt ATP binding to HSP90 and can be classified into ansamycins and non-ansamycins depending on whether they have a benzoquinone structure (Table 2).

**Ansamycins**

Ansamycins, including geldanamycin (GM), herbimycin A, and the macbecins, are antibiotics with anti-cancer activity and include the benzoquinone structure. These antibiotics induce death of tumor cells through HSP90 inhibition and degradation of the client proteins that are required for tumor cell survival and growth (Zhang and Zhang, 2011).

GM competitively binds to the ATP-binding pocket in the N-domain of HSP90 and inhibit chaperone activity of HSP90 via down-regulation of ATPase activity (Grenert et al., 1997). 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) is an analogue of GM with higher binding affinity and lower toxicity (Krishnamoorthy et al., 2005b; Karkoulis et al., 2010). 17-AAG also induces cell cycle arrest in G1 phase (Solit et al., 2002; Karkoulis et al., 2010). In addition, these effects of 17-AAG in cancer cells are similar to those in glioma stem cells (Sauvageot et al., 2009).

17-Dimethylaminoethylmimino-17-demethoxygelandamycin (17-DMA, alvespimycin), an analogue of 17-AAG, is a more potent and water-soluble derivative. 17-DMA binds to ATP binding site of HSP90 and inhibits ATP binding and chaperone activity of HSP90. Nuclear factor-κB (NF-κB) regulates anti-apoptotic proteins and oncogenes, such as c-FLIP, Bcl2, Mc1, and XIAP in chronic lymphocytic leukemia (PLL). 17-DMA binds to the ATP binding site of HSP90 and competes with the endogenous substrate ATP to inhibit ATPase activity. 17-DMA can also induce cell cycle arrest in G1 phase and down-regulate the expression of c-FLIP and XIAP, leading to apoptosis in cancer cells (Berezovski et al., 2002).

HSP90 inhibitors generally provide an overview on traditional HSP90 inhibitors and recent developments in HSP90 inhibition, including the mechanism of action, clinical trials, and potential therapeutic applications. HSP90 inhibitors have been studied for use as an anticancer agent, and some clinical trials are underway. In the first part of this review, we provide an overview on traditional HSP90 inhibitors and their effects on cancers. HSP90 inhibitors hamper HSP90 function by competitively binding to the ATP binding site of HSP90, blocking the interaction with co-chaperones, or modulating acetylation. In the second part, we present a novel site of HSP90, blocking the interaction with co-chaperones, or HSP90 function by competitively binding to the ATP binding site of HSP90 and inhibiting ATP binding and chaperone activity of HSP90. The combination of HSP90 inhibitors with other chemotherapeutic agents or targeted therapies may lead to synergistic effects and improve the efficacy of cancer treatment.

**References**

Berezovski, A., et al. (2002). Proc Natl Acad Sci USA, 99(24), 15485-15490.

Bolze, A., et al. (2004). Cancer Res, 64(14), 4654-4658.

Dickson, D. W., et al. (2013). Science, 342(6160), 1099-1105.

Grafone, V., et al. (2004). Cancer Res, 64(15), 5447-5453.

Karkoulis, P., et al. (2010). Br J Cancer, 103(2), 292-299.

Moasser, M. M., et al. (2011). Curr Opin Oncol, 23(5), 418-423.

Nath, A., et al. (2014). Cancer Metastasis Rev, 33(2), 291-302.

Quintas-Cardama, A., et al. (2017). Curr Opin Invest Drugs, 18(1), 1-11.

Satelli, R., et al. (2011). Cancer Metastasis Rev, 30(3-4), 415-435.
induces degradation of IκB kinase (IKK) and suppresses DNA binding of NF-κB. Consequently, 17-DMAG decreases transcription of NF-κB target genes and induces apoptosis (Hertlein et al., 2010). Her2/ErbB2 overexpression enhances cell growth and motility in breast and ovarian cancer. 17-DMAG-mediated HSP90 inactivation leads to degradation of Her2/ErbB2 (Niu et al., 2009). In non-small cell lung cancer (NSCLC), 17-DMAG treatment induces down-regulation of phospho-EGFR, phospho-Akt, and phospho-MAPK in EGFR-mutant cell lines than EGFR-WT cell line, and promotes cell apoptosis in EGFR-mutant cells (Kobayashi et al., 2012). In hepatocellular carcinoma (HCC), 17-DMAG induces apoptosis by degradation of survival-related proteins (Leng et al., 2012).

IPI-504 (retaspimycin hydrochloride) is a water-soluble analogue of 17-AAG and interacts with the ATP binding site of HSP90. IPI-504 inhibits myeloma tumor growth and has selective cytotoxicity to myeloma cancer cells compared with normal cells (Sydor et al., 2006). IPI-504 has anti-proliferation activity in several cancer cells through Her2/ErbB2 and Akt degradation. Tumor growth in vivo is also reduced by IPI-504 treatment through Her2/ErbB2 degradation (Leow et al., 2009). In diffuse large B-cell lymphoma (DLBCL) cell lines, IPI-504 inhibits cell growth and induces apoptosis. Among these cell lines, IPI-504-sensitive cell lines have high expression levels of phospho-Akt (Abramson et al., 2009).

Non-ansamycins

AUY992 (luminespib) binds to the ATP binding site in the N-domain of HSP90. AUY992 inhibits cell proliferation and induces G1/G2 cell cycle arrest and apoptosis in vitro. Furthermore, AUY992 inhibits growth and lung metastasis of b-Raf-mutated human melanoma tumor in vivo (Eccles et al., 2008). p23 is a co-chaperone of HSP90 and plays an important role in the activity of HSP90 and stabilization of client proteins by association with HSP90, and HSP90-p23 interaction requires ATP binding in HSP90 (Sullivan et al., 2002). In a Her2/ErbB-overexpressing estrogen receptor (ER)-positive breast cancer xenograft model, AUY992 reduces tumor growth by inducing dissociation of HSP90-p23 interaction and degradation of client proteins (Jensen et al., 2008). AUY992 induces apoptosis and depletion of Akt and IKK in acute myeloma leukemia (AML) cell lines and primary AML blasts (Walsby et al., 2013). AUY992 also inhibits cell growth and motility in hepatocellular carcinoma and pancreatic cancer cells and reduces growth factor-mediated and angiogenesis-related protein activation and vascularization in pancreatic cancer (Moser et al., 2012; Cheng et al., 2015).

BIIB021, an orally available inhibitor of HSP90, binds to the ATP binding pocket in the N-domain of HSP90. BIIB021 has anti-proliferation activity in various tumor cell lines in vitro and inhibits tumor growth in vivo. BIIB021 also induces degradation of HSP90 client proteins (Lundgren et al., 2009). In CLL cells, BIIB021 induces growth inhibition and apoptosis by the mitochondrial pathway and degradation of BCR-ABL protein. In addition, the BIIB021-induced apoptosis includes an autophagic response such as the formation of autophagosome by regulating the mTOR-Ulk1 pathway (He et al., 2016). 17-AAG and other ansamycin derivatives are inactive in cell lines expressing P-glycoprotein (P-gp) and/or multidrug resistance-associated protein 1 (MRP-1/ABCC1). In contrast, BIIB021 is active in these cell lines. Therefore, BIIB021 may be used for therapy of tumors protected by multidrug resistant (MDR) protein (Zhang et al., 2010a).

Debio0932 (CUDC-305) binds to the ATP binding site in the N-domain of HSP90. Debio0932 induces degradation of multiple oncoproteins, such as Akt, Raf-1, and Her2/ErbB2, and inhibits cell proliferation in various tissue-derived cancer cell lines. In glioblastoma, breast cancer, colorectal cancer, and NSCLC mouse models, debio0932 also induces degradation of client proteins and inhibits tumor growth (Bao et al., 2009).

STA-9090 (Ganetespib), a synthetic small molecule inhibitor, binds to the ATP binding site in the N-domain of HSP90 (Ying et al., 2012). STA-9090 induces proteasome-mediated degradation of EGFR, JAK2, and FLT3 which are essential for growth and activation of STAT, MAPK, and Akt. In addition, STA-9090 induces cell cycle arrest in G1 and G2/M phase (Proia et al., 2011). In Her2/ErbB2-positive breast cancer cells, STA-9090 inhibits cell proliferation, cell cycle, survival, and activation/phosphorylation of Her2/ErbB2. Furthermore,

### Table 2. Selected HSP90 inhibitors

| Target                  | Inhibitor            | References                        |
|-------------------------|----------------------|-----------------------------------|
| ATP-binding site        | Ansamycin            | Grenert et al., 1997              |
|                         | Geldanamycin         | Krishnamoorthy et al., 2013       |
|                         | 17-AAG (Tanespimycin) | Jez et al., 2003                   |
|                         | 17-DMAG (Alvespimycin)| Sydor et al., 2006                |
|                         | IPI-504 (retaspimycin hydrochloride) |                           |
|                         | Non-ansamycin        | Eccles et al., 2008                |
|                         | AUY922 (Luminespib)  | Lundgren et al., 2009             |
|                         | BIIB021              | Menezes et al., 2012              |
|                         | HSP990               | Bao et al., 2009                   |
|                         | Debio0932 (CUDC-305) | Ying et al., 2012                  |
|                         | STA-9090 (Ganetespib)| Woodhead et al., 2010             |
|                         | AT13387 (Onalespib)  | ChandraLaplaty et al., 2008        |
|                         | SNX-5422 (PF-04929113)|                                    |
| Deacetylation           | LAQ824               | Chen et al., 2005                  |
|                         | Romidepsin           | Yu et al., 2002                    |
|                         | Vorinostat (SAHA)    | Bali et al., 2005b                 |
the half-life of Her2/ErbB2 protein is decreased by STA-9090 treatment (Lee et al., 2018). In gastric cancer, STA-9090 inhibits proliferation and induces G2/M arrest of cell cycle and apoptosis. The receptor tyrosine kinase (RTK) signaling pathway is suppressed by STA-9090 treatment (Lee et al., 2017). STA-9090 also inhibits cell growth and induces apoptosis in AML and NSCLC (Shimamura et al., 2012; Lazenby et al., 2015).

Heat shock protein 990 (HSP990) binds to the ATP binding site in the N-domain of HSP90. During in vitro experiments, HSP990 inhibits ATPase activity of TNF receptor associated protein 1 (TRAP1), a mitochondrial HSP90, by more than 90%. HSP990 inhibits the activity of HSP90 and growth of various types of cancer cell lines and has suppressive activity in most various cancer patient-derived tumors ex vivo. In gastric cancer, breast cancer, AML, and NSCLC mouse models, HSP990 treatment also suppresses tumor growth (Menezes et al., 2012).

KW-2478 binds to HSP90α with high affinity. In multiple myeloma, KW-2478 induces degradation of client proteins such as FGFR3, c-Raf, and cyclin D1, growth inhibition, and apoptosis in vitro and in vivo (Nakashima et al., 2010).

AT13387 (onalespib) has affinity for HSP90 by binding in the ATPase site of the N-domain (Woodhead et al., 2010). AT13387 suppresses proliferation and survival of cell lines from different types of tumors. In glioma cell lines, AT13387 depletes survival-related client proteins and suppresses their downstream signaling pathway. As a result, proliferation, motility, angiogenesis, and survival are decreased. In NSCLC, AT13387 shows long duration of effects in vitro and in vivo (Graham et al., 2012; Canella et al., 2017).

SNX-5422/2112 (PF-04928473) binds to the ATP binding site in the N-domain of HSP90. SNX-5422/2112 induces HSP90 client protein degradation, such as Her2/ErbB2, Akt, and cyclin D1, and inhibits cell proliferation in Her2/ErbB2-overexpressing breast and ovarian cancers. In the body, SNX-5422 rapidly converts to SNX-2112, and SNX-2112 accumulates in tumors compared to normal tissues (Chandralapaty et al., 2008). The growth inhibition activity of SNX-2112 is higher than 17-AAG in multiple myeloma and other hematologic tumors. In multiple myeloma cells, SNX-2112 induces apoptosis by caspase activation and suppresses Akt and ERK activation. SNX-2112 inhibits tube formation of HUVEC cells by suppression of the eNOS/Akt pathway and osteoclastogenesis of multiple myeloma cells by down-regulation of ERK/c-Fos and PU.1 (Okawa et al., 2009).

HSP90 INHIBITORS BLOCKING DEACETYLATION OF HSP90

The molecular chaperone activity of HSP90 is also controlled by acetylation and deacetylation of K294 and K287 in the M-domain of HSP90α and HSP90β, respectively (Bali et al., 2005a; Scroggins et al., 2007; Nishio et al., 2008). Histone deacetylase 6 (HDAC6) deacetylates K294/K287 of HSP90, and the deacetylated HSP90α acts as a molecular chaperone. Acetylation of K294/K287 decreases the binding affinity of HSP90 to client proteins and co-chaperones (Bali et al., 2005a; Scroggins et al., 2007). In Her2/ErbB2-overexpressing breast cancer cell lines, vorinostat (also known as suberoylanilide hydroxamic acid (SAHA)) induces apoptosis via acetylation of HSP90, which dissociates Her2/ErbB2 from HSP90 and promotes polyubiquitinylation and degradation of Her2/ErbB2 (Bali et al., 2005b). LAQ824 induces acetylation of HSP90 in prostate cancer cells; the ATP binding activity of HSP90 is decreased as a result, and the androgen receptor is dissociated from HSP90 and degraded. Therefore, LAQ824 suppresses expression of androgen-induced prostate-specific antigen and induces anti-proliferation effects and apoptosis in prostate cancer cells. LAQ824 also reduces other HSP90 client protein levels (Chen et al., 2005). Romidepsin inhibits growth and induces apoptosis in wild type or mutant p53-expressing NSCLS cells. Romidepsin also reduces protein levels of ErbB1, ErbB2, Raf-1, and mutant p53, but not wild type p53. Romidepsin induces dissociation of mutant p53 and Raf-1 from HSP90, which is related with acetylation of HSP90 (Yu et al., 2002).

CLINICAL TRIALS OF TRADITIONAL HSP90 INHIBITORS FOR CANCER THERAPY

Since 17-AAG among HSP90 inhibitors first entered the clinical trial (Banerji et al., 2005a), many HSP90 inhibitors have entered clinical trials and are still underway. The HSP90 inhibitors that have been investigated in clinical trials are presented in Table 3. Clinical trials of HSP90 inhibitors were performed as HSP90 inhibitor monotherapy or combination therapy with other anti-cancer reagents for validation of safety, anti-cancer activity, and dosing schedule and dosage. While inhibitors of ansamycin and non-ansamycin classes have not been FDA approved, romidepsin and vorinostat among HDAC inhibitors have been FDA approved.

Another strategy that uses HSP90 in clinical trials is to suppress drug resistance using HSP90 inhibitor. Her2/ErbB2 and mutated EGFR are one of the proteins that cause drug resistance. Because Her2/ErbB2 and EGFR are clients of HSP90, Her2/ErbB2 and EGFR are one of the proteins that cause drug resistance. Because Her2/ErbB2 and EGFR are clients of HSP90, clinical trials with HSP90 inhibitors were designed to overcome drug resistance by these proteins. In Her2/ErbB2-overexpressing breast cancer, 17-AAG, STA-9090, and AUY922 were used in Phase I and II clinical trials to overcome Her2/ErbB2-mediated resistance to trastuzumab (Herceptin, humanized anti-Her2/ErbB2 monoclonal antibody). The results proved that HSP90 inhibition may be used to overcome the trastuzumab resistance (Modi et al., 2007; Kong et al., 2016; Jhaveri et al., 2017). In addition, to overcome the resistance of EGFR mutation-positive lung cancer to erlotinib (Tarceva, receptor tyrosine kinase inhibitor), Phase I and II clinical trials using AUY922 have been performed (Johnson et al., 2015).

NOVEL CLASS OF HSP90 INHIBITORS INDUCING CLEAVAGE OF HSP90

Recently, it has been reported that HSP90 is cleaved by various stimuli. Cleavage of HSP90 is induced by various stimuli such as UVB irradiation (Chen et al., 2009), ascorbate/menadione (Beck et al., 2009, 2012), androgenopholide (Liu et al., 2014), HDAC inhibitors (Park et al., 2015), proteosome inhibitors (Park et al., 2017), tumor necrosis factor (TNF) (Fritsch et al., 2016), a combination of gefitinib and vorinostat (Park et al., 2019), etc. (Table 4). Therefore, cleavage of HSP90 can be considered another mechanism of HSP90 regulation.

https://doi.org/10.4062/biomolther.2019.051
Table 3. Clinical trials of anti-cancer therapy with HSP90 inhibitors

| HSP90 inhibitor | Phase | Tumor type | Reference |
|-----------------|-------|------------|-----------|
| 17-AAG (Tanespimycin) | I | Relapsed or refractory acute myeloid leukemia | Walker et al., 2013 |
| | II | Metastatic or locally advanced, unresectable breast cancer | Rajan et al., 2011 |
| | II | Metastatic melanoma | Solit et al., 2008; Pacey et al., 2012 |
| | I | Solid tumor | Tse et al., 2008 |
| | I | b-Raf or NRAS mutated melanoma | Banerji et al., 2008 |
| | I | Relapsed / refractory pediatric solid tumor | Weigel et al., 2007 |
| | I | Refractory advanced cancer | Ramanathan et al., 2005 |
| | I/I | Relapsed or relapsed and refractory multiple myeloma | Richardson et al., 2011 |
| | I | Relapsed multiple myeloma | Richardson et al., 2010 |
| | I | Her2/ErbB2-overexpressed breast cancer | Modi et al., 2007 |
| 17-DMAG (Alvespimycin) | I | Chronic lymphocytic leukemia/small lymphatic lymphoma | Maddocks et al., 2016 |
| | I | Advanced solid tumor | Pacey et al., 2011; Jhaveri et al., 2012 |
| | I | Acute myeloma leukemia | Lancet et al., 2010 |
| | I | Advanced malignancies | Kummar et al., 2010 |
| AUY922 (Luminespib) | IB/II | Her2/ErbB2-positive metastatic breast cancer | Kong et al., 2016 |
| | II | Advanced pancreatic cancer | Renouf et al., 2016 |
| | II | Gastrointestinal stromal cancer | Sessa et al., 2013; Doi et al., 2014; Bendell et al., 2015 |
| | I/I | EGFR-mutant lung cancer | Johnson et al., 2015 |
| BIIB021 | I | Advanced solid tumor | Saif et al., 2014 |
| | I | Refractory metastatic or locally advanced solid tumor | Hong et al., 2013 |
| | I | Gastrointestinal stromal tumor | Dickson et al., 2013 |
| Debio0932 (CUDC-305) | I | Advanced cancer | Isambert et al., 2015 |
| STA-9090 (Ganetespib) | I | Her2/ErbB2-positive metastatic breast cancer | Jhaveri et al., 2017 |
| | II | Metastatic castrate-resistant prostate cancer | Thakur et al., 2016 |
| | II | Non-small cell lung cancer | Ramalingam et al., 2015 |
| | II | KRAS mutated and WT metastatic colorectal cancer | Cercek et al., 2014 |
| | I | Advanced hepatocellular carcinoma | Goyal et al., 2015 |
| | II | Metastatic breast cancer | Jhaveri et al., 2014 |
| | II | Advanced non-small lung cancer | Socinski et al., 2013 |
| | I | Solid malignancies | Goldman et al., 2013 |
| HSP9090 | I | Advanced solid malignancies | Spreafico et al., 2015 |
| KW-2478 | I/I | Multiple myeloma | Cavenagh et al., 2017 |
| | I | B-cell malignancies | Yong et al., 2016 |
| LAQ824 | I | Advanced solid tumor | de Bono et al., 2008 |
| AT13387 (Onalespib) | I | Advanced solid tumor | Do et al., 2015; Shapiro et al., 2015 |
| IPI-504 (Retasipimycin hydrochloride) | I | Gastrointestinal stromal tumor, soft-tissue sarcoma | Wagner et al., 2013 |
| | II | Castrate-resistant prostate cancer | Oh et al., 2011 |
| Romidepsin | II | Metastatic castrate-resistant prostate cancer | Molife et al., 2010 |
| SNX-5422 (PF-04929113) | I | Refractory solid tumor | Infante et al., 2014 |
| | I | Refractory solid tumor malignancies and lymphomas | Rajan et al., 2011 |
| Vorinostat (SAHA) | I/I | Locally advanced breast cancer | Tu et al., 2014 |
| | I/I | Metastatic breast cancer | Ramaswamy et al., 2012 |

HSP90 cleavage can be divided into enzymatic cleavage and non-enzymatic cleavage. The enzymatic cleavage generates an approximately 55 kDa fragment of HSP90 via caspase 10 activation, and the non-enzymatic cleavage generates an approximately 70 kDa fragment via chemical degradation by reactive oxygen species (ROS). There are some substances that have HSP90 cleavage activity, but it has not yet been determined whether enzymes are engaged in the process.

Chemicals and UV inducing enzymatic cleavage of HSP90

The enzymatic cleavage of HSP90 is induced by histone deacetylase inhibitors (including vorinostat), proteasome inhibitors (including MG132), and UVB irradiation. We found cleavage of HSP90 when treated with the histone deacetylase inhibitor vorinostat in leukemia cells (Park et al., 2015). HSP90 was also cleaved by other histone deacetylase inhibitors, sodium butyrate and valproic acid (Park et al., 2015). Vorinostat induces ROS generation in acute T cell leukemia cell line.
The novel class of HSP90 inhibitors inducing cleavage of HSP90

| Cleavage type          | Inhibitor                        | References               |
|------------------------|----------------------------------|--------------------------|
| Enzymatic cleavage     | Histone deacetylase inhibitors   | Park et al., 2015        |
|                        | Proteasome inhibitors            | Park et al., 2017        |
|                        | Ultra-violet irradiation         | Chen et al., 2009        |
| Non-enzymatic cleavage | Ascorbate/Menadione               | Beck et al., 2009, 2012  |
|                        | Oxidative stress (H₂O₂)          | Castro et al., 2019      |
| Others (undefined)     | Tumor necrosis factor (TNF)      | Fritsch et al., 2016     |
|                        | Andrographolide                  | Liu et al., 2014         |
|                        | β-Lapachone                      | Wu et al., 2016          |
|                        | 17-AAG (Tanespimycin)            | Karkoulis et al., 2010   |
|                        | As(III) and MMA(III)             | Shen et al., 2008        |

(Ruefli et al., 2001). On the other hand, generation of ROS by several stimuli leads to activation of caspase and triggers apoptosis in various types of cancer cells through an extrinsic or intrinsic pathway (Kim and Chung, 2007). According to our results, ROS-induced caspase 10 activation is responsible for enzymatic cleavage of HSP90 after treatment with vorinostat (Park et al., 2015). Furthermore, vorinostat-induced HSP90 cleavage needs newly synthesized protein(s), and Vitamin D up-regulating protein 1 (VDUP-1) may be one of the candidate substances (Park et al., 2015). Vorinostat was previously reported to increase the expression level of the VDUP-1 gene (Butler et al., 2002), and VDUP-1 negatively regulates thioredoxin, a cellular antioxidant (Junn et al., 2000).

We also found that MG132, a proteasome inhibitor, induces HSP90 cleavage through a mechanism similar to that of vorinostat treatment (Park et al., 2017). Although the mRNA level of VDUP-1 was not changed after treatment with MG132, the protein level of VDUP-1 was significantly increased. E3 ubiquitin ligase Itch-mediated ubiquitination and proteasomal degradation is involved in the regulation of VDUP-1 protein level (Zhang et al., 2010b). Therefore, MG132 may up-regulate the VDUP-1 protein level by inhibiting the proteasome activity and blocking the proteasomal degradation of VDUP-1. Another antioxidant glutathione was also decreased by MG132 treatment. In short, MG132 also induces HSP90 enzymatic cleavage via generation of ROS and subsequent activation of caspase 10.

UVB irradiation induces HSP90 cleavage by activating the Fas/Fas ligand axis (Chen et al., 2009). In this case, Fas ligand secretion and Fas expression were increased by UVB irradiation. Caspase 8 was activated by interaction with the FADD domain of active Fas, and HSP90 was cleaved by caspase 8-mediated active caspase 10. Importantly, apoptosis of cells increased when HSP90 was down-regulated and cells harboring mutation on the cleavage site of HSP90 showed better survival compared with control cells upon UVB irradiation. Therefore, it is likely that the HSP90 cleavage is not merely a side effect of caspase activation but an essential process for the regulation of apoptosis.

Chemicals inducing non-enzymatic cleavage of HSP90

In leukemia cells (K562 cell line), ascorbate/menadione (asc/men) treatment induces HSP90 cleavage with a molecular weight of approximately 70 kDa. The HSP90 cleavage is selectively induced in tumor cells, but not in normal cells. The asc/men-induced HSP90 cleavage triggers degradation of HSP90 client proteins, including Bcr-Abl, and the cleavage of HSP90 is induced by ROS generation and inhibited by antioxidant (Beck et al., 2009). The cleavage of HSP90 is induced by Fenton reaction in the presence of redox-active iron. The cleavage site in this reaction is between I131 and G132 in HSP90α and I126 and G127 in HSP90β (Beck et al., 2012).

In Jurkat cells, oxidative stress (H₂O₂) induces iron-dependent HSP90 cleavage with a molecular weight of approximately 70 kDa, and the HSP90 cleavage inversely correlates with cell proliferation. Cleaved HSP90 accumulates as aggregates in an insoluble form, and actin also aggregates in sequence. Using a cell-free in vitro model, it was proved that the cleaved HSP90 gains another function to directly induce aggregation of actins (Castro et al., 2019).

Others inducing cleavage of HSP90

TNF induces HSP90 cleavage depending on Cathepsin D (CtsD). TNF treatment in U937 (human myeloid leukemia) cells induced HSP90 cleavage in a time-dependent manner, which was blocked by treatment with peptatin A (PepA), a CtsD inhibitor. In this case, HSP90 was observed to be cleaved into 60 kDa and 40 kDa fragments and it was concluded using the mutagenesis technique that the 465th tyrosine residue may be the target of HSP90 cleavage. Apoptosis of U937 cells expressing mutant HSP90 (Y465W) by TNF was decreased compared to control U937 cells (Fritsch et al., 2016).

Andrographolide (andro), a diterpenoid lactone isolated from Andrographis paniculata, has anti-inflammatory activity and inhibits cell transformation through v-Src degradation (Liang et al., 2008). When temperature-sensitive v-Src-expressing cell line (ts-v-Src; RK3E cell line) was treated with andro, 40 kDa fragments of HSP90 were also detected with v-Src degradation. Andro-induced HSP90 cleavage was related with a decrease of v-Src and cell apoptosis. In this phenomenon, andro-mediated ROS generation plays an important role in HSP90 cleavage and v-Src suppression. Furthermore, in leukemia cells, andro-induced HSP90 cleavage was correlated with BCR-ABL down-regulation and apoptosis (Liu et al., 2014).

The novel anti-cancer drug β-Lapachone (β-lap) induces HSP90 cleavage in NAD(P)H:quione oxidoreductase-1 (NQO1)-expressing lung and prostate cancer cells and HUVEC cells. The cleavage of HSP90 is induced by β-lap-mediated ROS generation, and the cleavage of HSP90 and down-regulation of client proteins are restored by antioxidant treatment. NQO1-mediated activation of β-lap triggers a futile cycle, and NQO1-dependent quinones cannot cleave HSP90, unlike β-lap. Therefore, the futile re-
HSP90 inhibitors

- Inhibition of ATP binding
- Blocking of interaction with co-chaperones
- Acetylation
- Cleavage

Reduction of HSP90 activity → Degradation of client proteins → Tumor cell growth survival

Fig. 1. Diagram of HSP90 inhibitor-mediated tumor cell suppression. HSP90 inhibitors are known to inhibit the binding of ATP, block binding to co-chaperones and regulate acetylation to inhibit the activity of HSP90. In addition, the cleavage of HSP90 discussed in this paper appears to suppress the activity of HSP90. Inhibition of HSP90 by HSP90 inhibitors reduces chaperone activity and inhibits growth and survival of tumor cells through degradation of the HSP90 client proteins.

dox cycle of β-lap may generate ROS, and the chemical structure of β-lap is a critical factor for HSP90 cleavage (Wu et al., 2016).

As described earlier, 17-AAG inhibits HSP90 by binding to the ATP-binding pocket of HSP90. In human urinary bladder cancer cells, 17-AAG induces cell apoptosis and down-regulation of client proteins, and the cleavage of HSP90 was also examined (Karkoulis et al., 2010). The detailed action mechanism involved in 17-AAG has not been defined yet.

Arsenic compounds arsenite (As(III)) and monomethylarsonic acid (MMA(III)) induce ROS-mediated apoptosis and HSP90 cleavage. It was reported that the NADPH inhibitor, diphenyleneiodonium chloride (DPI), inhibit As(III)-induced apoptosis and that HSP90 cleavage is also reduced by DPI treatment. In addition, JNK inhibitor, SP600125, blocks HSP90 cleavage, whereas the ERK inhibitor PD98059 does not. Therefore, As(III) and MMA(III) induce HSP90 cleavage via NADPH and JNK activation, thereby inducing cell apoptosis (Shen et al., 2008).

CONCLUSIONS

HSP90 is a molecular chaperone that supports folding and stabilization of the client proteins. Likely because many client proteins of HSP90 are required for cancer cell survival and growth, most cancer cells express HSP90 more highly than normal cells (Ferrarin et al., 1992; Sharp and Workman, 2006; Neckers and Workman, 2012; Miyata et al., 2013). Various inhibitors of HSP90 have been studied as anticancer drugs and clinical trials are underway. Most of the traditional inhibitors target ATP binding or deacetylation of HSP90, and thereby block the molecular chaperone activity of HSP90, resulting in degradation of the client proteins and increased cell death in cancer cells. Recently, several studies including ours have shown that the cleavage of HSP90 is correlated with degradation of client proteins and directly or indirectly affects the survival and growth of cancer cells (Shen et al., 2008; Chen et al., 2009; Liu et al., 2014; Fritsch et al., 2016; Wu et al., 2016). In addition, HSP90 cleavage inducing reagents, such as β-lap and vorinostat (Ramaswamy et al., 2012; Tu et al., 2014; Park et al., 2015; Wu et al., 2016), are also used for anti-cancer therapy. Therefore, it can be carefully postulated that chemicals inducing HSP90 cleavage may have anticancer activity. Taken together, the present results show that HSP90 cleavage may be another mechanism of HSP90 inhibitors and targeting of HSP90 cleavage is potentially another strategy for cancer chemotherapy (Fig. 1). We are presently screening chemicals that can induce HSP90 cleavage and are planning to verify whether they have anticancer activity when used alone or in combination. The results can be helpful to understand the mechanism of HSP90 inhibition in several aspects and may provide novel candidate drugs for cancer therapy.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

ACKNOWLEDGMENTS

This research was supported by grants from the National Research Foundation (NRF-2018R1A2B6002504) funded by the Ministry of Science and ICT in the Republic of Korea.

REFERENCES

Abramson, J. S., Chen, W., Juszczynski, P., Takahashi, H., Neuberg, D., Kuto, J. L., Takeyama, K. and Shipp, M. A. (2009) The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br. J. Haematol. 144, 358-366.

Bali, P., Pranapat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., Seto, E. and BHalla, K. (2005a) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729-26734.

Bali, P., Pranapat, M., Swaby, R., Fiskus, W., Yamaguchi, H., Balasis, M., Rocha, K., Wang, H. G., Richon, V. and BHalla, K. (2005b) Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin. Cancer Res. 11, 6382-6389.

Banerji, U., Affolter, A., Judson, I., Marais, R. and Workman, P. (2008) BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol. Cancer. Ther. 7, 737-739.

Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmonds, L., Maloney, A., Raymond, F., Campbell, M., Walton, M., Lakhanie, S., Kaye, S., Workman, P. and Judson, I. (2009a) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23, 4152-4161.

Banerji, U., Walton, M., Raymond, F., Grimshaw, R., Kelland, L., Valenti, M., Judson, I. and Workman, P. (2005b) Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin. Cancer Res. 11, 3669-3676.

www.biomolther.org
Cavenagh, J., Oakervee, H., Baetiong-Caguioa, P., Davies, F., Castro, J. P., Fernando, R., Reeg, S., Meinl, W., Almeida, H. and Beck, R., Dejeans, N., Glorieux, C., Creton, M., Delaive, E., Dieu, Bao, R., Lai, C. J., Qu, H., Wang, D., Yin, L., Zifcak, B., Atoyan, R., Chen, L., Meng, S., Wang, H., Bali, P., Bai, W., Li, B., Atadja, P., Bhal, Chen, H., Xia, Y., Fang, D., Hawke, D. and Lu, Z. (2009) Caspase-
Leow, C. C., Cheshbrough, J., Coffman, K. T., Fazenbaker, C. A., Gooya, J., Weng, D., Coats, S., Jackson, D., Jallal, B. and Chang, Y. (2009) Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol. Cancer Ther. 8, 2131-2141.

Liang, F. P., Lin, C. H., Kuo, C. D., Chao, H. P. and Fu, S. L. (2008) Suppression of v-Src transformation by andrographolide via degradation of the v-Src protein and attenuation of the Erk signaling pathway. J. Biol. Chem. 283, 5023-5033.

Liu, S. H., Lin, C. H., Liang, F. P., Kuo, C. D., Alam, M. M., Maiti, B., Hung, S. K., Chi, C. W., Sun, C. M. and Fu, S. L. (2014) Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy. Biochem. Pharmacol. 88, 229-242.

Lundgren, K., Zhang, H., Breken, J., Huser, N., Powell, R. E., Timple, N., Busch, D. J., Neely, L., Sensitaffar, J. L., Yang, Y. C., McKenzie, A., Friedman, J., Scannevin, R., Kamal, A., Hong, K., Kasibhatla, S. R., Boehm, M. F. and Burrows, F. J. (2009) BIBO21, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein 90. Mol. Cancer Ther. 8, 921-929.

Maddocks, K., Hertlein, E., Chen, T. L., Wagner, J. A., Ling, Y., Flynn, J., Phelps, M., Johnson, A. J., Byrd, J. C. and Jones, J. A. (2016) A Phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia: small lymphocytic lymphoma. Leuk. Lymphoma 57, 2212-2215.

Maddocks, D. L., Taverna, P., Jensen, M. R., Abrams, T., Stuart, D., Maddocks, K., Hertlein, E., Chen, T. L., Wagner, A. J., Ling, Y., Flynn, M., Gooya, J., Weng, D., Coats, S., Jackson, D., Jallal, B. and Chang, Y. (2008) Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol. Cancer Ther. 8, 2131-2141.

Liu, S. H., Lin, C. H., Liang, F. P., Kuo, C. D., Alam, M. M., Maiti, B., Hung, S. K., Chi, C. W., Sun, C. M. and Fu, S. L. (2014) Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy. Biochem. Pharmacol. 88, 229-242.

Lundgren, K., Zhang, H., Breken, J., Huser, N., Powell, R. E., Timple, N., Busch, D. J., Neely, L., Sensitaffar, J. L., Yang, Y. C., McKenzie, A., Friedman, J., Scannevin, R., Kamal, A., Hong, K., Kasibhatla, S. R., Boehm, M. F. and Burrows, F. J. (2009) BIBO21, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein 90. Mol. Cancer Ther. 8, 921-929.
S., Gutierrez, M., Crandon, S., Zein, W. M., Jain, L., Mannargудi, B., Figg, W. D., Houk, B. E., Shnайдман, M., Brega, N. and Gi-accone, G. (2011) A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumors malignancies and lymphomas. *Clin. Cancer Res.* 17, 6831-6839.

Ramalingam, S., Goss, G., Rosell, R., Schmid-Bindert, G., Zaric, B., Andric, Z., Bondarenko, I., Komov, D., Ceric, T., Khuri, F., Samar-zija, M., Filip, E., Cieuleanu, T., Hirsh, V., Wehler, T., Spicer, J., Sal-gia, R., Shapiro, G., Sheldon, E., Teofilovic, F., Vukovic, V. and Fennell, D. (2015) A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GAL-AXX-1). *Ann. Oncol.* 26, 1741-1748.

Ramanathan, R. K., Trump, D. L., Eiseman, J. L., Belani, C. P., Agar-wala, S. a., Zhuhowski, E. G., Lan, J., Potter, D. M., Ivy, S. P., Ra-malingam, S., Brufsky, A. M., Wong, M. K., Tutcho, S. and Egorin, M. J. (2005) Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamo)-17-de ethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. *Clin. Cancer Res.* 11, 3385-3391.

Ramaswamy, B., Fiskus, W., Cohen, B., Pellegrino, C., Hershman, D., Ramalingam, S., Goss, G., Rosell, R., Schmid-Bindert, G., Zaric, B., Richardson, P. G., Chanan-Khan, A. A., Alsina, M., Albitar, M., Ber, Ruefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R., Tainton, C., Sessa, C., Shapiro, G. I., Bhalla, K., Britten, C., Jacks, K. S., Mita, M., Papadimitrioukopolou, V., Plu, tard, T., Samuel, T. A., Akimov, M., Quad, t, C., Fernandez-Ibarra, C., Lu, H., Bailey, S., Chica, S. and Banerji, U. (2013) First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. *Clin. Cancer Res.* 19, 3671-3680.

Shapiro, G. I., Kwak, E., Dezube, B. J., Yule, M., Ayerton, J., Lyons, J. and Mahadevan, D. (2015) First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors. *Clin. Cancer Res.* 21, 87-97.

Sharp, S. and Workman, P. (2006) Inhibitors of the HSP90 molecular chaperone: current status. *Adv. Cancer Res.* 95, 323-349.

Shen, S. C., Yang, L. Y., Lin, H. Y., Wu, C. Y., Su, T. H. and Chen, Y. C. (2008) Reactive oxygen species-dependent HSP90 protein cleavage participates in arsenical (As+) - and MMA(+) -induced apoptosis through inhibition of telomerase activity via JNK activation. *Toxicol. Appl. Pharmacol.* 229, 239-251.

Shimamura, T., Perera, S. A., Foley, K. P., Sang, J., Rodig, S. J., Inoue, T., Chen, L. L., De, Carretero, J. L., Li, Y. C., Yin, W., Barsoum, J., Wang, K. K. and Shapiro, G. I. (2012) Ganetespib (STB-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in vitro and in vivo models of non-small cell lung cancer. *Clin. Cancer Res.* 18. 4973-4985.

Soedini, M. A., Goldman, J., El-Hariry, I., Koczynras, M., Vukovic, V., Horn, L., Paschold, E., Salgia, R., West, H., Segust, L. V., Bonomi, P., Brahmer, J., Chen, L. C., Sandler, A., Belani, C. P., Webb, T., Harper, H., Huberman, M., Ramalingam, S., Wong, K. K., Teo, filovic, F., Guo, W. and Shapiro, G. I. (2013) A multicenter phase II study of ganetespib monotherapy in patients with genetically defined advanced non-small cell lung cancer. *Clin. Cancer Res.* 19, 3068-3077.

Solit, D. B., Osman, I., Polsky, D., Panagreas, K. S., Daud, A., Goydos, J., Teitcher, J., Wolchok, J. D., Germino, F., Krown, S. E., Coin, D., Rosen, N. and Chapman, P. B. (2008) Phase II trial of 17-allylamino-17-de ethoxygeldanamycin in patients with meta static melanoma. *Clin. Cancer Res.* 14, 8302-8307.

Sood, D. B., Zheng, F. F., Drobnjak, M., Munster, P. N., Higgin, B., Ver, bel, D., Heller, G., Tong, W., Cordon-Cardo, C., Agus, D. B., Scher, H. L. and Rosen, N. (2002) 17-Allylamino-17-de ethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. *Clin. Cancer Res.* 8, 896-903.

Spraul, C., Defo, J. P., De Mattos-Arruda, L., Berge, Y., Rodon, J., Cottura, E., Bedard, P. L., Akimov, M., Lu, H., Pain, S., Kaag, A., Sui, L. L. and Cortes, J. (2015) A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. *Br. J. Cancer* 112, 650-659.

Sreedhar, A. S., Almar, K., Csermely, P. and Shen, Y. F. (2004) Hsp90 isoforms: functions, expression and clinical importance. *FEBS Lett.* 568, 11-15.

Sullivan, W. P., Owen, B. A. and Toft, D. O. (2002) The influence of ATP and p32 on the conformation of hsp90. *J. Biol. Chem.* 277, 45942-45948.

Sud, S. R., Normant, E., Pien, C. S., Porter, J. R., Ge, J., Grenier, L., Pak, R. H., Ali, J. A., Dembski, M. S., Dudak, J., Patterson, J., Penders, C., Pink, M., Read, M. A., Sang, J., Woodward, C., Zhang, Y., Grayzel, D. S., Wright, J., Barrett, J. A., Palombella, V. J., Adams, J. and Tong, J. K. (2006) Development of 17-allyl amino-17-de ethoxygeldanamycin hydroquinone hydrochloride (IP1-504), an anti-cancer agent directed against Hsp90. *Proc. Natl. Acad. Sci. U.S.A.* 103, 17408-17413.

Thakur, M. K., Heilbrun, L. K., Sheng, S., Stein, M., Liu, G., Antonara, kis, E. S., Vaishampayan, U., Dziczik, S. H., Li, L., Freeman, S.,
Tse, A. N., Klimstra, D. S., Gonen, M., Shah, M., Sheikh, T., Tissieres, A., Mitchell, H. K. and Tracy, U. M. (1974) Protein synthesis

Tu, Y., Hershman, D. L., Bhalla, K., Fiskus, W., Pellegrino, C. M., An-Voldborg, B. R., Damstrup, L., Spang-Thomsen, M. and Poulsen, H.

Tiburcio, P. D., Choi, H. and Huang, L. E. (2014) Complex role of HIF

Weigel, B. J., Blaney, S. M., Reid, J. M., Safgren, S. L., Bagatell, R., Walsby, E. J., Lazenby, M., Pepper, C. J., Knapper, S. and Burnett, A.

M. J., Kelsen, D. and Schwartz, G. K. (2008) A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Cancer Res. 14, 6704-6711.

Tu, Y., Hershman, D. L., Bhalla, K., Fiskus, W., Pellegrino, C. M., Andreopoulou, E., Makower, D., Kalinsky, K., Fehn, K., Fineberg, S., Negassa, A., Montgomery, L. L., Wiechmann, L. S., Alpaugh, R., K., Huang, M. and Sparano, J. A. (2014) A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res. Treat. 146, 145-152.

Voldborg, B. R., Damstrup, L., Spang-Thomsen, M. and Poulsen, H. S. (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol. 8, 1197-1206.

Wagner, A. J., Chugh, R., Rosen, L. S., Morgan, J. A., George, S., Gordon, M., Dunbar, J., Normant, E., Grayzel, D. and Demetri, G. D. (2013) A phase I study of the HSP90 inhibitor relasipimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin. Cancer Res. 19, 6020-6029.

Walker, A. R., Klisovic, R., Johnston, J. S., Jiang, Y., Geyer, S., Kefauver, C., Binkley, P., Byrd, J. C., Grever, M. R., Garzon, R., Phillips, M. A., Martucci, G., Blum, K. A. and Blum, W. (2013) Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk. Lymphoma 54, 1996-2002.

Walsby, E. J., Lazenyi, M., Pepper, C. J., Knapper, S. and Burnett, A. K. (2013) The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. Br. J. Haematol. 161, 57-67.

Weigel, B. J., Blaney, S. M., Reid, J. M., Safgren, S. L., Bagatell, R., Kersey, J., Neglia, J. P., Ivy, S. P., Ingle, A. M., Whitesell, L., Gilbertson, R. J., Krailo, M., Ames, M. and Adamson, P. C. (2007) A phase I study of 17-allylamino-17-demethoxygeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children’s Oncology Group study. Clin. Cancer Res. 13, 1789-1793.

Welch, W. J. (1993) How cells respond to stress. Sci. Am. 268, 56-64.

Woodhead, A. J., Angove, H., Carr, M. G., Chessari, G., Congreve, M., Coyle, J. E., Cosme, J., Graham, B., Day, P. J., Downham, R., Fazal, L., Feltell, R., Figueroa, E., Frederickson, M., Lewis, J., McMenamin, R., Murray, C. W., O’Brien, M. A., Parra, L., Patel, S., Phillips, T., Rees, D. C., Rich, S., Smith, D. M., Trewartha, G., Vinkovic, M., Williams, B. and Woolford, A. J. (2010) Discovery of (2,4-dihydroxy-5-isopropylphenyl)-5-(4-methylpiperazin-1-yl)-methyl-1,3-dihydrodioxol-2-yl)methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J. Med. Chem. 53, 5956-5969.

Wu, Y., Wang, X., Chang, S., Lu, W., Liu, M. and Pang, X. (2016) beta-Lapachone induces NAD(P)H:quione oxidoreductase-1 and oxidative stress-dependent heat shock protein 90 cleavage and inhibits tumor growth and angiogenesis. J. Pharmacol. Exp. Ther. 357, 466-475.

Xia, Y., Shen, S. and Verma, I. M. (2014) NF-kappaB, an active player in human cancers. Cancer Immunol. Res. 2, 823-830.

Xu, Y., Jin, J., Xu, X., Shao, Y. W. and Fan, Y. (2017) JAK2 variations and functions in lung adenocarcinoma. Tumour Biol. 39, 1010428317711140.

Yang, W., Du, Z., Sun, L., Foley, K. P., Proia, D. A., Blackman, R. K., Zhou, D., Inoue, T., Tatsuta, N., Sang, J., Ye, S., Acquaviva, J., Ogawa, L. S., Wada, Y., Barsoum, J. and Koya, K. (2012) Gane-tespib, a unique triazole-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol. Cancer Ther. 11, 475-484.

Yoeli-Lerner, M. and Toker, A. (2006) Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5, 603-605.

Yong, K., Cavet, J., Johnson, P., Morgan, G., Williams, C., Nakashima, D., Akhaga, S., Oakevve, H. and Cavenagh, J. (2016) Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. Br. J. Cancer 114, 7-13.

Yu, X., Guo, Z. S., Marcu, M. G., Neckers, L., Nguyen, D. M., Chen, G. A. and Schrump, D. S. (2002) Modulation of p53, ErbB1, and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. Br. J. Haematol. 114, 404-513.

Zhang, H., Neely, L., Lundgren, K., Yang, Y. C., Lough, R., Timple, N. and Burrows, F. (2010a) BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int. J. Cancer 126, 1226-1234.

Zhang, H. and Zhang, L. (2011) Ansamycin class of natural product Hsp90 inhibitors. In Encyclopedia of Cancer (M. Schwab, Ed.), pp. 198-201. Springer Berlin Heidelberg, Berlin, Heidelberg.

Zhang, P., Wang, C., Gao, K., Wang, D., Mao, J., An, J., Xu, C., Wu, D., Yu, H., Liu, J. O. and Yu, L. (2010b) The ubiquitin ligase itch regulates apoptosis by targeting thioredoxin-interacting protein for ubiquitin-dependent degradation. J. Biol. Chem. 285, 8869-8879.

Zuehlke, A. and Johnson, J. L. (2010) Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 93, 211-217.